Integrating liquid biopsy and mutational signatures to advance precision oncology
Abstract
The effective application of precision oncology in solid tumors remains challenging due to genetic heterogeneity and the absence of actionable alterations in some cancers. In this review, we discuss the integration of liquid biopsy and mutational signatures as a potential framework to address these limitations by enabling longitudinal detection of mutational processes that arise during tumor development and evolution. Together, these complementary approaches hold substantial promise for enhancing cancer screening, refining diagnosis, and guiding personalized therapeutic strategies, thereby advancing the field of precision oncology.
Fields of Study & Subjects
Cancer Genomics and Diagnostics
Cancer Cells and Metastasis
PARP inhibition in cancer therapy
Publication details
- Journal / source
- npj Precision Oncology
- Publisher
- Springer Science and Business Media LLC
- Volume
- 10
- Issue
- 1
- Publication date
- 23 February 2026
- Language
- EN